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13. Other issues 
~]An investigation into the prevalence of the use of 
complementary (CM) and over the counter (OTC) medicines (MEDS) 
by patients (pts) in an adult Cystic Fibrosis centre 
J. Redfern, M.E. Dodd, A.M. Jones, A.K. Webb. Manchester Adult Cystic Fibrosis 
Centre, Manchester, UK 
Introduction: Pts at the Manchester Adult Cystic Fibrosis centre are offered an annual 
review where they are seen by all the members of the multi-disciplinary team. The 
pharmacist takes a full drag history including CM and OTC MEDS. These additional 
MEDS are then assessed to identify whether there is any disease or drag interaction 
with these products. The concept of CM MEDS is explained and advice is offered 
about suitability, if any evidence is available. 
Method: 167 pts were seen during annual review by the Specialist CF Pharmacist and 
were asked to report any MEDS they took, in addition to those prescribed by the CF 
centre 
Results: CM MEDS: Of the 167 pts seen, 50, (30%) (28 male, 22 female) reported 
taking at least 1 CM medicine in the past year with some taking as many as 5 per day 
(leR-hand graph). 
The most popular CM MEDS are shown in the right-hand graph. The vitamins identified 
are in addition to or instead of those prescribed by the CF centre. Other CM MEDS 
taken include: Chinese medicine, omega 3, ginseng, acidophilus, cats claw, rescue 
remedy, turmeric, passiftora, ftaxseed, wild yam, dolomite and herbal sleeping aids. 
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OTC MEDS: 38 pts (23%) (19 males, 19 females) reported taking OTC MEDS. 23 pts 
took simple analgesics, paracetamol and ibupro fen. 6 reported taking cough MEDS (one 
formulated for use by horses!). The remaining were cold remedies and skin products. 
Conclusion: A significant number of CF patients regularly take CM MEDS and OTC 
MEDS. Additionally it appears that whilst some patients are reluctant o adhere to 
conventional MEDS, they are prepared to take CM MEDS even when they had been 
made aware that they lacked the controls of licensed MEDS in the UK. 
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1~ Three methods of monitoring adherence in a long-term trial in 
Cystic Fibrosis 
M. Elkins 1 , M. Robinson 1, C. Moriarty 1 , J. Sercombe 2, B. Rose 3, C. Harbour 3, 
R Bye 1'2, NHSCF Study Group. 1Royal Prince Alfred HosTital, 2Woolcock 
Institute, 3 University of Sydney, Sydney, Australia 
Aim: To compare three methods of adherence monitoring in a clinical trial. 
Methods: In a double blind, parallel trial, 164 stable subjects with CF aged ~> 6 yrs 
were randomly allocated to inhale 4 d mL of 7% (HS) or 0.9% (NS) saline, twice 
daily, each with a taste masking agent, for 48 weeks. Adherence with the inhalations 
was monitored in three ways: diary cards completed weekly (DC); return of used 
and unused ampoules at scheduled visits (RA); and, in a random subset of  145 
patients, a device which logged nebuliser use (LD). Subjects were only informed 
of the logging device on completion of  the trial and were given the opportunity to 
anonymously decline consent o have their data downloaded. 
Results: No subjects declined to have the data downloaded. Complete adherence 
datasets were obtained from 130/145 (90%) of  subjects monitored via LD, which 
was significantly better than the proportion of subjects via DC (p < 0.01) and RA 
(p < 0.01). The remaining results are for data from the 129 subjects for whom 
all monitoring methods were at least 85% complete. Overall adherence via DC 
(76±27%) was significantly higher than via RA (67±28%) (p < 0.01), which was 
significantly higher than via LD (61±31%) (p < 0.01). HS and NS group adherence 
did not significantly differ 74±27 vs 78±28% (DC), 66±27 vs 69±30% (RA), 
64±29 vs 59±33% (LD) (all p>0.36).  Adherence was significantly higher in 
children than adults 86±18 vs 65±31% on DC, and 74±24 vs 61±31% on RA 
(both p < 0.01), but this difference was non-significant on LD. Adherence declined 
over the year of participation, via all three methods. 
Conclusion: Monitoring via LD returned significantly more complete datasets, and 
may give a more accurate assessment of adherence. 
[ ] T h e  use of complementary therapies in an Australian 
Cystic Fibrosis clinic 
J. Morton, S. Dixon, R. McDonald. Department of Respiratory Medicine, Sydney 
Children ~' Hospital, Sydney, Australia 
Aims: The aim of this study was to document a number of aspects of complemen- 
tary therapy use in a CF population including usage prevalence, types of therapy, 
perception of efficacy, cost and side effects. 
Methods: A comprehensive questionnaire about complementary therapy (CT) 
answered anonymously relating to multiple aspects of CT use and a parental 
assessment of disease severity. 
Results: 70 questionnaires were completed from 100 distributed. The mean age of 
the patients was 6.72 years (18 months-22 years) and 37 respondents were male, 
21 patients (30%) reported regular CT use and 41 patients (70%) denied any CT 
use. Complementary therapies used included herbal treatments (77%), chiropractic 
(29%), massage (29%), homeopathy (15%), acupuncture (5%). Only 19% of the 
patients had made their physician aware. Patients using CT were generally older 
(mean age 12.15 yrs) and had more significant and deteriorating disease with 43% 
classed "moderate to severe" in the CT group versus 12% in the non CT group. 
Yearly hospitalisation rates were 1.01 admissions in the CT group versus 0.59 in the 
non CT group. Patients using CT tended to have higher numbers of conventional 
medications. Of  the CT users 14% of parents felt their CT treatment was very 
effective, 43% thought possibly so and the remainder remained hopeful. No major 
side effects were noted. 
Conclusions: Roles of  complementary therapy use in CF are significant and often 
unreported. Although most of  these therapies are probably harmless, some have the 
potential for harm. There is a serious lack of  well designed clinical trials to assess 
efficacy of these treatments in CE Proactive and non judgmental discussion by the 
CF physician regarding these therapies hould be encouraged. 
1• Lung HRCT and MRI findings in pediatric patients with 
Cystic Fibrosis 
RA. Daltro, T.W. Folescu, I.R. Sad, R.C. Domingues, L. Rodrigues, L.C. Cruz, 
L.Y.S. Higa. Instituto Fernandes Figueira, Rio de Janeiro, Brazil 
High resolution computer tomography (HRCT) has been used to grade the severity 
of the disease and to follow up the course of lung changes. It seems of utmost 
importance to develop novel techniques, with no ionizing radiation burden, and which 
can provide regional lung function data. Magnetic resonance imaging (MRI) is known 
as a noninvasive method, which uses safe contrast and does not require ionizing 
radiation. The aim of the study is to compare the accuracy of MRI imaging with 
HRCT in the detection of the main pulmonary aspects of CE 
Sixteen patients from a CF reference center, 9 male, mean age 11.4 yo (ranged 7 21 yo), 
were included in the study and submitted to a lung HRCT and a pulmonary parenchyma 
MRI. HRCT and MRI images were analyzed by two observers by consensus for the 
presence of bronchiectasis, bronchial wall thickening, mucus plugging, "tree in bud" 
pattern and consolidation. 
Results: 
Abnormalities HRCT MRI 
igtotal % igtotal % 
Bronchiectasis 14/16 87.5 % 11/16 68.7% 
Bronchial wall thickening 16/16 100% 12/16 75% 
Mucus Plugging 13/16 81.2% 12/16 75% 
"Tree in bud" patlern 14/16 87.5% 12/16 75% 
Consolidation 11/16 68.7% 13/16 81.2% 
Mucus plugging and "tree in bud" pattern were found in both exams. Bronchiectasis and 
bronchial wall thickening were more evident on CT images, while consolidation was 
more frequent on MRI images. There are some limitations for MRI when compared with 
CT: more expensive, longer breath-hold time, performed only in cooperative patients 
(> 7 yo), image distortions can be caused by motion artifacts. MRI in CF patients may 
be a noninvasive method for assessment of CF chronic lung involvement, uses safe 
contrast which does not require ionizing radiation and is an able tool for evaluating CF 
in young patients. Improvements in MR techniques will allow us to make even more 
powerful approaches. 
